Re: Uncle is dying please help

[Guest guest]

,

The possibility of recovery has a great deal to do with the willingness

of your uncle to do what it may be suggested he do. It may also depend

on someone else---yourself or another person, doing what needs to be

done.

My suggestion is that you get in touch with the person who runs this

site: http://survivecancerfoundation.org

I would telephone him to see what he says. It is very likely he will

recommend raw juices, in which case, someone will have to prepare them

for your uncle. There will of course be other things that will be

recommended.

The person who runs that site recently helped very significantly a

young man with " incurable " bladder cancer.

[Guest guest]

ONe more approval:2nd today 3-Jan-07 10:34 am Oncolytics

Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating

REOLYSIN® in Combination with Gemcitabine

Wednesday January 3, 10:30 am ET

CALGARY, Jan. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

( " Oncolytics " ) (TSX:ONC, NASDAQ:ONCY) announced today that it has

received a letter of approval from the U.K. Medicines and Healthcare

products Regulatory Agency (MHRA) for its Clinical Trial Application

(CTA) to begin a clinical trial using intravenous administration of

REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with

advanced cancers including pancreatic, lung and ovarian. The

principal investigators are Dr. Johann de Bono of The Royal Marsden

NHS Foundation Trust and The Institute of Cancer Research, London and

Professor Jeff of the University of Glasgow and the Beatson

Oncology Centre in Glasgow, Scotland. Gemcitabine is used in patients

with lung, pancreatic and ovarian cancers and is also used widely in

the treatment of many other types of cancers.

" The combination of REOLYSIN® and gemcitabine was synergistic in

preclinical studies, " said Dr. Brad , President and CEO of

Oncolytics. " The data gathered in this study is expected to assist

the company in further defining the optimal path to product

registration. Drug combination studies allow us to investigate

REOLYSIN® with drugs that are part of the current standard of care. "

Preclinical studies conducted at Cornell University demonstrated that

the combination of gemcitabine and REOLYSIN® was synergistic against

selected cancer cell lines. This work was verified by additional

studies conducted by the U.S. National Cancer Institute (NCI).

This trial (REO 009) has two components. The first is an open-label,

dose-escalating, non-randomized study of REOLYSIN® given

intravenously with gemcitabine every three weeks. A standard dosage

of gemcitabine will be delivered with escalating dosages of REOLYSIN®

intravenously. A maximum of three cohorts will be enrolled in the

REOLYSIN® dose escalation portion. The second component of the trial

will immediately follow and will include the enrolment of a further

12 patients at the maximum dosage of REOLYSIN® in combination with a

standard dosage of gemcitabine.

Eligible patients include those who have been diagnosed with advanced

or metastatic solid tumours including pancreatic, lung and ovarian

cancers that are refractory (have not responded) to standard therapy

or for which no curative standard therapy exists. The primary

objective of the trial is to determine the Maximum Tolerated Dose

(MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing

schedule and safety profile of REOLYSIN® when administered in

combination with gemcitabine. Secondary objectives include the

evaluation of immune response to the drug combination, the body's

response to the drug combination compared to chemotherapy alone and

any evidence of anti-tumour activity.

In the U.K. and the U.S., approximately 280,000 people are diagnosed

with pancreatic, lung and ovarian cancers every year.